The research investigated the efficacy and safety of various Chinese medicine injections, used in combination with Western medicine, for patients with stable angina pectoris through a systematic approach. From their respective initial entries to July 8, 2022, PubMed, Cochrane Library, EMBASE, Web of Science, CNKI, Wanfang, VIP, and SinoMed were thoroughly searched to locate randomized controlled trials (RCTs) evaluating Chinese medicine injection combined with conventional Western medicine for treating stable angina pectoris. genetic overlap Literature screening, data extraction, and bias risk evaluation of the included studies were carried out by two independently working researchers. Stata 151's functionality was leveraged to perform the network Meta-analysis. A total of 52 randomized controlled trials, involving 4,828 patients, were included in the analysis, each of whom received treatment from 9 Chinese medicine injections (Danhong Injection, Salvia Miltiorrhiza Polyphenol Hydrochloride Injection, Tanshinone Sodium A Sulfonate Injection, Salvia Miltiorrhiza Ligustrazine Injection, Dazhu Hongjingtian Injection, Puerarin Injection, Safflower Yellow Pigment Injection, Shenmai Injection and Xuesaitong Injection). Through a network meta-analysis, it was determined that (1) strategies for improving the effectiveness of angina pectoris are The surface under the cumulative ranking curve (SUCRA) demonstrated a treatment order consistent with conventional Western medicine, starting with Salvia Miltiorrhiza Ligustrazine Injection and ending with Dazhu Hongjingtian Injection, progressively including Tanshinone Sodium A Sulfonate Injection, Danhong Injection, and other listed injections. SUCRA's strategy, aligning with established Western medicine, consisted of a sequential administration of Salvia Miltiorrhiza Ligustrazine Injection, Puerarin Injection, Danhong Injection, Salvia Miltiorrhiza Polyphenol Hydrochloride Injection, Shenmai Injection, Xuesaitong Injection, Safflower Yellow Pigment Injection, Tanshinone Sodium A Sulfonate Injection, and Dazhu Hongjingtian Injection; this regimen was intended to elevate high-density lipoprotein cholesterol (HDL-C). Following a conventional Western medicine approach, SUCRA administered injections in this order: Danhong Injection, Shenmai Injection, Safflower Yellow Pigment Injection, Xuesaitong Injection, Tanshinone Sodium A Sulfonate Injection, and, lastly, Dazhu Hongjingtian Injection; this strategy was designed to lower low-density lipoprotein cholesterol (LDL-C). In a regimen consistent with conventional Western medicine, SUCRA utilized Safflower Yellow Pigment Injection, Danhong Injection, Shenmai Injection, Tanshinone Sodium A Sulfonate Injection, Dazhu Hongjingtian Injection, and Xuesaitong Injection; (5) Safety measures were a primary focus. The concurrent use of Chinese medicine injections and standard Western treatments resulted in a notably lower rate of adverse reactions than the control group experienced. Stable angina pectoris treatment outcomes were shown to be enhanced by the combined use of Chinese medicine injections with conventional Western medicine, with a notable increase in safety, based on the existing data. screening biomarkers The aforementioned conclusion, significantly influenced by the limited number and quality of the incorporated studies, requires further support by means of high-quality studies for confirmation.

In rat plasma and urine, the UPLC-MS/MS method was established for the quantitative analysis of acetyl-11-keto-beta-boswellic acid (AKBA) and beta-boswellic acid (-BA), the chief active components of Olibanum and Myrrha extracts within the Xihuang Formula. Examining the interplay of compatibility and pharmacokinetic behaviors of AKBA and -BA in rats involved comparing healthy control groups to those exhibiting precancerous breast lesions. Comparative analysis of -BA's AUC (0-t) and AUC (0-) metrics following compatibility demonstrated statistically significant elevations (P<0.005 or P<0.001) in comparison with the RM-NH and RM-SH cohorts. Conversely, T (max) measurements exhibited a significant reduction (P<0.005 or P<0.001), and C (max) measurements displayed a significant increase (P<0.001). The evolution of AKBA's trends matched precisely the evolution of -BA's trends. When the RM-SH group was compared, the T (max) exhibited a decrease (P<0.005), the C (max) increased (P<0.001), and the absorption rate showed an increase in the Xihuang Formula's normal group. The urinary excretion data following compatibility exhibited a decrease in the rate and overall amount of -BA and AKBA, yet no statistically significant variation was apparent. Significant increases in AUC (0-t) and AUC (0-) of -BA were observed (P<0.005) in the breast precancerous lesion group, relative to the normal Xihuang Formula group. Simultaneously, T (max) exhibited a significant increase (P<0.005), while the clearance rate demonstrated a decrease in the breast precancerous lesion group. Concerning AKBA, the area under the curve (AUC) from zero to time t (AUC(0-t)) and from zero to negative infinity (AUC(0-)) exhibited an increasing trend, and both the in vivo retention time and the clearance rate were influenced accordingly, but there was no significant difference in comparison with the normal group. The cumulative urinary excretion and urinary excretion rate of -BA and AKBA were lower in pathological conditions. This signifies that the in vivo processing of -BA and AKBA is impacted by pathological states, resulting in decreased excretion of these prototype drugs, exhibiting contrasting pharmacokinetic characteristics from their behavior in typical physiological conditions. This study established a UPLC-MS/MS analytical method suitable for in vivo pharmacokinetic investigations of -BA and AKBA. Through this study, the groundwork was laid for the development of novel approaches to Xihuang Formula dosage forms.

A surge in living standards and modifications in work habits have led to a rising rate of abnormal glucose and lipid metabolism in modern humanity. Despite the potential improvement of related indicators through lifestyle modifications and/or the use of hypoglycemic and lipid-lowering medications, currently there are no drugs dedicated to treating glucose and lipid metabolism disorders. Hepatitis C virus core protein binding protein 6 (HCBP6), a newly discovered target, modulates triglyceride and cholesterol levels in response to bodily fluctuations, thereby impacting irregular glucose and lipid metabolism. Ginsenoside Rh2's upregulation of HCBP6 expression is supported by relevant studies, whereas studies exploring Chinese herbal medicines' effects on HCBP6 remain scarce. In addition, the precise three-dimensional configuration of HCBP6 is yet to be established, and the discovery of substances capable of influencing its function is not currently progressing rapidly. Consequently, eight frequently used Chinese herbal medicines, notable for their role in regulating abnormal glucose and lipid metabolism, were chosen to examine the effect of their combined saponins on the expression of HCBP6. Predicting the three-dimensional structure of HCBP6 was undertaken, subsequently followed by molecular docking analyses with saponins sourced from eight different Chinese herbal remedies to rapidly identify potential active components. Analysis of the results revealed a trend for all total saponins to increase HCBP6 mRNA and protein expression; gypenosides demonstrated the most effective upregulation of HCBP6 mRNA, and ginsenosides exhibited the most potent upregulation of HCBP6 protein. Prediction of protein structures through the Robetta website and subsequent analysis using SAVES led to the determination of reliable protein structures. AZD9291 In addition to being collected from the website and literature, saponins were docked with the forecast protein; the constituents of the saponins displayed advantageous binding characteristics to the HCBP6 protein. The expected benefits of this study encompass conceptual frameworks and actionable strategies for the development of novel drugs from Chinese herbal sources aimed at controlling glucose and lipid metabolism.

Oral administration of Sijunzi Decoction in rats, followed by UPLC-Q-TOF-MS/MS analysis, identified the components that enter the bloodstream. A mechanistic study of Sijunzi Decoction in treating Alzheimer's disease utilized network pharmacology, molecular docking, and validation in experimental settings. Mass spectra, coupled with data from the literature and databases, allowed for the determination of the components of Sijunzi Decoction that contribute to blood replenishment. In the pursuit of identifying potential targets for Alzheimer's disease treatment, the blood-entering components from the previous discussion were cross-referenced against PharmMapper, OMIM, DisGeNET, GeneCards, and TTD. STRING was implemented in the subsequent phase to build a protein-protein interaction network (PPI). The Gene Ontology (GO) annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment procedures were conducted using DAVID. To visualize the data, Cytoscape 39.0 was utilized. By utilizing AutoDock Vina and PyMOL, a molecular docking study was conducted on the blood-entering components interacting with potential targets. The phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway, revealed by the KEGG analysis, was selected for experimental confirmation through animal trials. The serum samples, after treatment, showed the presence of 17 components originating from the blood. Among the key ingredients of Sijunzi Decoction for Alzheimer's disease treatment are poricoic acid B, liquiritigenin, atractylenolide, atractylenolide, ginsenoside Rb1, and glycyrrhizic acid. Among the molecular targets of Sijunzi Decoction in treating Alzheimer's disease are HSP90AA1, PPARA, SRC, AR, and ESR1. The components exhibited robust binding to the targets, as demonstrated by molecular docking. Hence, our hypothesis centers on the potential link between Sijunzi Decoction's therapeutic action against Alzheimer's disease and the PI3K/Akt, cancer treatment, and mitogen-activated protein kinase (MAPK) signaling pathways.